Worldwide collaboration for orphan drug designation

Affiliations

¹ European Medicines Agency, 30 Churchill Place, Canary Wharf, E14 5EU London, UK.
² Office of Orphan Products Development, US Food and Drug Administration, Silver Spring, Maryland 20993, USA.
³ European Medicines Agency, 30 Churchill Place, Canary Wharf, E14 5EU London, UK; and Läkemedelsverket, Dag Hammarskjölds vägen 42, 75103 Uppsala, Sweden.
⁴ European Medicines Agency, 30 Churchill Place, Canary Wharf, E14 5EU London, UK; and European Organisation for Rare Diseases (Eurordis), 96 rue Didot, 75014 Paris, France.
⁵ Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau (PFSB), Ministry of Health, Labour and Welfare (MHLW), 1-2-2 Kasumigaseki Chiyoda-ku, Tokyo, 100-8916 Japan.
⁶ European Medicines Agency, 30 Churchill Place, Canary Wharf, E14 5EU London, UK; and Universidade de Lisboa, Faculdade de Farmácia, 1649-003 Lisboa, Portugal.

Segundo Mariz et al. Nat Rev Drug Discov. 2016.

. 2016 Jun 1;15(6):440-1.

doi: 10.1038/nrd.2016.80.

¹ European Medicines Agency, 30 Churchill Place, Canary Wharf, E14 5EU London, UK.
² Office of Orphan Products Development, US Food and Drug Administration, Silver Spring, Maryland 20993, USA.
³ European Medicines Agency, 30 Churchill Place, Canary Wharf, E14 5EU London, UK; and Läkemedelsverket, Dag Hammarskjölds vägen 42, 75103 Uppsala, Sweden.
⁴ European Medicines Agency, 30 Churchill Place, Canary Wharf, E14 5EU London, UK; and European Organisation for Rare Diseases (Eurordis), 96 rue Didot, 75014 Paris, France.
⁵ Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau (PFSB), Ministry of Health, Labour and Welfare (MHLW), 1-2-2 Kasumigaseki Chiyoda-ku, Tokyo, 100-8916 Japan.
⁶ European Medicines Agency, 30 Churchill Place, Canary Wharf, E14 5EU London, UK; and Universidade de Lisboa, Faculdade de Farmácia, 1649-003 Lisboa, Portugal.

No abstract available

References